CRANFORD, N.J., Oct. 4 /PRNewswire/ — New American
Therapeutics, Inc., announced today that it acquired all U.S.
rights to manufacture, market and sell the antiviral topical drug
Denavir® owned by Novartis.  Denavir (1% penciclovir
cream) is a highly selective and potent topical antiviral treatment
indicated for the treatment of recurrent herpes labialis (cold
sores) in adults and children 12 years of age and older.  The
topical antiviral cream market in the U.S. is valued at
approximately $100 million annually.

Novartis has agreed to provide limited transitional services to
New American Therapeutics to allow for a smooth transition of the
business to New American Therapeutics.  

“Denavir offers patients a proven therapy for the treatment of
herpes labialis.  Likewise, the established revenue stream
will provide New American Therapeutics with the capital required to
expand our growing infrastructure and product line,” stated Alan L.
Rubino, CEO and President of New American Therapeutics.  “We
are enthusiastic about advancing the commercial efforts of this
important asset.”

Denavir 1% penciclovir topical cream is a safe and effective
medicine when used as directed. Patients should read the package
directions before using Denavir.  Possible side effects
include headache or irritation at the site of application. Patients
should contact their doctor if they experience these symptoms as a
result of using Denavir.  Patients should consult their doctor
before using 1% penciclovir topical cream if they are allergic to
penciclovir or acyclovir (Zovirax®), or any other drugs, or are
pregnant or nursing.

About New American Therapeutics, Inc.New American
Therapeutics, Inc. is a privately held, specialty pharmaceutical
company based in Cranford, N.J. that acquires, markets and develops
products in select therapeutic areas.CONTACT:

Alan L. Rubino  908-372-8108Email:

SOURCE